Real-Life Discontinuation of TKIS

About 60% patients with CML in deep persistent molecular remission (MR4, MR4.5 or MR5), relapse after TKI discontinuation. Here we reported our real-life single center experience.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research